McKesson Corporation $MCK Shares Bought by Two Sigma Securities LLC

Two Sigma Securities LLC boosted its position in McKesson Corporation (NYSE:MCK) by 398.3% during the second quarter, Holdings Channel.com reports. The institutional investor owned 2,332 shares of the company’s stock after purchasing an additional 1,864 shares during the period. Two Sigma Securities LLC’s holdings in McKesson were worth $1,762,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of MCK. University of Texas Texas AM Investment Management Co. acquired a new position in McKesson in the fourth quarter valued at approximately $25,000. Swiss RE Ltd. purchased a new position in McKesson in the fourth quarter valued at $26,000. Delos Wealth Advisors LLC acquired a new position in shares of McKesson in the second quarter worth about $27,000. State of Wyoming acquired a new position in shares of McKesson in the second quarter worth about $29,000. Finally, Kingdom Financial Group LLC. purchased a new stake in shares of McKesson during the 4th quarter worth about $33,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Stock Up 0.2%

McKesson stock opened at $895.59 on Monday. McKesson Corporation has a 52-week low of $679.65 and a 52-week high of $999.00. The firm has a market capitalization of $104.42 billion, a price-to-earnings ratio of 23.97, a PEG ratio of 1.76 and a beta of 0.30. The company has a fifty day simple moving average of $833.31 and a 200-day simple moving average of $843.29.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, topping the consensus estimate of $9.56 by $0.37. The firm had revenue of $105.38 billion for the quarter, compared to the consensus estimate of $103.88 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period last year, the firm posted $8.26 earnings per share. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, research analysts anticipate that McKesson Corporation will post 44.65 EPS for the current fiscal year.

McKesson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Tuesday, September 1st will be paid a $0.94 dividend. This is a positive change from McKesson’s previous quarterly dividend of $0.82. The ex-dividend date of this dividend is Tuesday, September 1st. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio is 8.78%.

Insider Buying and Selling

In related news, Director Bradley E. Lerman sold 301 shares of McKesson stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $892.33, for a total transaction of $268,591.33. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Napoleon B. Rutledge, Jr. sold 133 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $764.00, for a total value of $101,612.00. Following the transaction, the chief accounting officer directly owned 632 shares in the company, valued at $482,848. This trade represents a 17.39% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 22,988 shares of company stock valued at $17,920,808. 0.06% of the stock is currently owned by company insiders.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Expansion into precision medicine: McKesson agreed to acquire privately held Precision Medicine Group for approximately $2.25 billion. Precision Medicine provides clinical research, laboratory testing and commercialization services for biotechnology and pharmaceutical companies, giving McKesson greater exposure to oncology, personalized medicine and specialty care. McKesson Doubles Down on Healthcare Growth With Precision Medicine Acquisition
• Positive Sentiment: Higher-growth service mix: The acquisition is expected to strengthen McKesson’s clinical research and commercialization capabilities and deepen relationships with biopharmaceutical companies and oncology practices. Investors may view the transaction as a way to reduce reliance on lower-margin pharmaceutical distribution and participate in growth tied to new drug development. What Does McKesson Gain From Its Push Into Oncology And Clinical Research?
• Neutral Sentiment: Portfolio repositioning amid workforce changes: Coverage noted layoffs at Rx Savings while McKesson plans the Precision Medicine acquisition. The combination highlights an ongoing reallocation of resources, although the near-term effect on earnings and integration costs remains uncertain. Amid Layoffs, McKesson Plans Acquisition
• Negative Sentiment: Cybersecurity incident disclosed: McKesson reported discovering a cybersecurity incident on August 25 after the ShinyHunters group claimed it had stolen patient data. The company’s investigation and any resulting regulatory, remediation, privacy or reputational costs could weigh on sentiment, although the ultimate scope and financial impact were not yet clear. McKesson Discloses Breach After ShinyHunters Claims Patient Data Theft

Analysts Set New Price Targets

Several brokerages recently weighed in on MCK. Robert W. Baird set a $1,015.00 price target on McKesson in a research note on Thursday, August 6th. Barclays raised their price objective on McKesson from $925.00 to $1,000.00 and gave the company an “overweight” rating in a report on Wednesday, August 19th. Morgan Stanley restated an “overweight” rating on shares of McKesson in a research report on Friday, August 7th. Royal Bank Of Canada started coverage on McKesson in a research note on Wednesday, August 19th. They set a “sector perform” rating and a $845.00 target price for the company. Finally, JPMorgan Chase & Co. decreased their target price on McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Fourteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $973.44.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.